Schrödinger, Inc. SDGR
31.52 USD -0.89 (-2.75%)
At closeNov 11, 2026, 4:03 PM EST
31.51 -0.01 -0.03%
After hours · Nov 11, 4:03 PM ET
31.36 Day range 34.00
10.95 52-week range 34.00
- YTD
- +76.29%
- 1 year
- +72.24%
Benzinga news
benzinga.com TD Cowen Maintains Buy on Schrodinger, Raises Price Target to $36 TD Cowen analyst Brendan Smith maintains Schrodinger (NASDAQ:SDGR) with a Buy and raises the price target from $31 to $36.
benzinga.com Schrodinger Q3 2026 Earnings Call Transcript Schrodinger (NASDAQ:SDGR) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Schrodinger Q3 Adj. EPS $(0.50) Beats $(0.70) Estimate, Sales $64.491M Beat $47.258M Estimate Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $(0.70) by 28.57 percent. This is a 12.28 percent increase over losses of $(0.57)…
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com UBS Maintains Neutral on Schrodinger, Raises Price Target to $21 UBS analyst Kevin Caliendo maintains Schrodinger (NASDAQ:SDGR) with a Neutral and raises the price target from $19 to $21.
benzinga.com Keybanc Maintains Overweight on Schrodinger, Raises Price Target to $32 Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and raises the price target from $20 to $32.
benzinga.com TD Cowen Maintains Buy on Schrodinger, Raises Price Target to $31 TD Cowen analyst Brendan Smith maintains Schrodinger (NASDAQ:SDGR) with a Buy and raises the price target from $20 to $31.- benzinga.com BMO Capital Maintains Outperform on Schrodinger, Raises Price Target to $30 BMO Capital analyst Gary Nachman maintains Schrodinger (NASDAQ:SDGR) with a Outperform and raises the price target from $24 to $30.
benzinga.com Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You A look at the stocks that are owned by Cathie Wood's Ark Invest and Donald Trump.
benzinga.com Vicor, Arm Holdings, Micron Technology And Other Big Stocks Moving Higher On Thursday U.S. stocks rose; Vicor jumped 13.5% on a new license, while Generac surged 19.6% on an Amazon deal. Securitize and biotech shares rallied.
benzinga.com Schrödinger Announces Formation Of Tectora, New Biotechnology Company; Tectora Secures $55M Series A Investment From NEA And RA Capital Management Schrödinger, Inc. (NASDAQ:SDGR) today announced the formation of Tectora, a new biotechnology company it co-founded with New Enterprise Associates (NEA) and RA Capital Management, focused on…- benzinga.com Schrödinger Rolls Out Early Access Version Of Bunsen Schrödinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop…
benzinga.com Anthropic Is Going All In on Drug Discovery Just as Pharma Stops Talking About AI Anthropic launches Claude Science for researchers as PwC data shows AI mentions in pharma M&A decline, signaling a shift in AI adoption.- benzinga.com Morgan Stanley Maintains Equal-Weight on Schrodinger, Lowers Price Target to $17 Morgan Stanley analyst Vikram Malhorta maintains Schrodinger (NASDAQ:SDGR) with a Equal-Weight and lowers the price target from $19 to $17.
benzinga.com Schrodinger Affirms FY2026 Sales Guidance of $273.000M-$293.000M vs $252.752M Est Schrodinger (NASDAQ:SDGR) affirms FY2026 sales outlook from $273.000 million-$293.000 million to $273.000 million-$293.000 million vs $252.752 million estimate.- benzinga.com Schrodinger Q1 Adj. EPS $(0.63), Inline, Sales $58.587M Beat $48.002M Estimate Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.63) per share which met the analyst consensus estimate. This is a 1.56 percent increase over losses of $(0.64) per share from the same…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $20 Keybanc analyst Brandon Nispel maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $25 to $20.
- benzinga.com UBS Maintains Neutral on Schrodinger, Lowers Price Target to $13 UBS analyst Michael Yee maintains Schrodinger (NASDAQ:SDGR) with a Neutral and lowers the price target from $18 to $13.
- benzinga.com Reported earlier, Schrodinger Sees FY2026 Sales $273.000M-$293.000M vs $301.358M Est Schrodinger (NASDAQ:SDGR) sees FY2026 sales of $273.000 million-$293.000 million vs $301.358 million analyst estimate.
benzinga.com Schrodinger Q4 Sales $87.200M Beat $83.396M Estimate Schrodinger (NASDAQ:SDGR) reported quarterly sales of $87.200 million which beat the analyst consensus estimate of $83.396 million by 4.56 percent. This is a 1.25 percent decrease over sales of…- benzinga.com Earnings Scheduled For February 25, 2026
benzinga.com Earnings Preview For Schrodinger 
benzinga.com Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - benzinga.com Schrödinger Reports 2025 Progress, Highlights Physics+AI Platform Growth, Strategic Collaborations And Proprietary Therapeutics; Outlines 2026 Priorities For Platform Scaling And Clinical Advancements Schrödinger, Inc. (NASDAQ:SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on advancing its…
- benzinga.com TD Cowen Maintains Buy on Schrodinger, Lowers Price Target to $24 TD Cowen analyst Brendan Smith maintains Schrodinger (NASDAQ:SDGR) with a Buy and lowers the price target from $33 to $24.
benzinga.com Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $25 Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $28 to $25.- benzinga.com UBS Initiates Coverage On Schrodinger with Neutral Rating, Announces Price Target of $18 UBS analyst Michael Yee initiates coverage on Schrodinger (NASDAQ:SDGR) with a Neutral rating and announces Price Target of $18.
- benzinga.com B of A Securities Upgrades Schrodinger to Buy, Maintains Price Target to $24 B of A Securities analyst Michael Ryskin upgrades Schrodinger (NASDAQ:SDGR) from Neutral to Buy and maintains the price target from $24 to $24.
- benzinga.com Schrodinger Affirms FY2025 Sales Guidance of $243.440M-$257.460M vs $249.717M Est Schrodinger (NASDAQ:SDGR) affirms FY2025 sales outlook from $243.440 million-$257.460 million to $243.440 million-$257.460 million vs $249.717 million estimate.
- benzinga.com Schrodinger Q3 Adj. EPS $(0.57) Beats $(0.71) Estimate, Sales $54.324M Beat $51.557M Estimate Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.71) by 19.26 percent. This is a 34.48 percent increase over losses of $(0.87)…
benzinga.com Earnings Scheduled For November 5, 2025 - benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
- benzinga.com Copernic Catalysts Surpasses Final Technical Milestone For Its Jointly-Developed Ammonia Synthesis Catalyst With Schrodinger Copernic Catalysts, Inc. (Copernic) today announced that, in collaboration with Schrödinger, Inc. (Nasdaq: SDGR), the companies have surpassed the final technical milestone for their…
benzinga.com Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $28 Keybanc analyst Scott Schoenhaus maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $30 to $28.- benzinga.com Expert Outlook: Schrodinger Through The Eyes Of 5 Analysts
- benzinga.com Goldman Sachs Initiates Coverage On Schrodinger with Neutral Rating, Announces Price Target of $19 Goldman Sachs analyst Andrea Newkirk initiates coverage on Schrodinger (NASDAQ:SDGR) with a Neutral rating and announces Price Target of $19.
- benzinga.com Schrödinger Announces A Separation And Release Of Claims Agreement With Dr. Geoffrey Porges As Executive Vice President And CFO -SEC Filing-SEC Filing
- benzinga.com What 4 Analyst Ratings Have To Say About Schrodinger
- benzinga.com Morgan Stanley Maintains Equal-Weight on Schrodinger, Lowers Price Target to $19 Morgan Stanley analyst Vikram Malhorta maintains Schrodinger (NASDAQ:SDGR) with a Equal-Weight and lowers the price target from $28 to $19.
benzinga.com This Cisco Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - benzinga.com Citigroup Downgrades Schrodinger to Neutral, Lowers Price Target to $20 Citigroup analyst David Lebowitz downgrades Schrodinger (NASDAQ:SDGR) from Buy to Neutral and lowers the price target from $35 to $20.
benzinga.com This AZZ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - benzinga.com Barclays Initiates Coverage On Schrodinger with Overweight Rating, Announces Price Target of $25 Barclays analyst Peter Lawson initiates coverage on Schrodinger (NASDAQ:SDGR) with a Overweight rating and announces Price Target of $25.
- benzinga.com Schrodinger Affirms FY2025 Sales Guidance of $243.44M-$257.46M vs $253.20M Est Schrodinger (NASDAQ:SDGR) affirms FY2025 sales outlook from $243.44 million-$257.46 million to $243.44 million-$257.46 million vs $253.20 million estimate.
- benzinga.com Schrodinger Q2 Adj. EPS $(0.65) Beats $(0.83) Estimate, Sales $54.76M Beat $52.03M Estimate Schrodinger (NASDAQ:SDGR) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.83) by 21.31 percent. This is a 1.52 percent increase over losses of $(0.66)…
- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Keybanc Maintains Overweight on Schrodinger, Lowers Price Target to $30 Keybanc analyst Aleksey Yefremov maintains Schrodinger (NASDAQ:SDGR) with a Overweight and lowers the price target from $32 to $30.
- benzinga.com Schrödinger Reports 22% Response Rate in Early Trial for Drug-Resistant B-Cell Cancers Schrödinger, Inc. (NASDAQ:SDGR) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell…
- benzinga.com Schrödinger To Present Phase 1 Clinical Data On MALT1 Inhibitor SGR-1505 At EHA Annual Congress And International Conference On Malignant Lymphoma Company to host webcast to review data on Thursday, June 12, 2025 at 8:00 a.m. ETSchrödinger, Inc. (NASDAQ:SDGR) today announced that initial Phase 1 clinical data for SGR-1505, its investigational…